Literature DB >> 503641

Protein-bound homocyst(e)ine in normal subjects and in patients with homocystinuria.

S S Kang, P W Wong, N Becker.   

Abstract

A method was developed to quantitate protein-bound homocyst(e)ine using 2-mercaptoethanol. Protein-bound homocyst(e)ine was discovered in the plasma from normal individuals, ranging from 0.5--2.2 nmole/ml. In two obligatory heterozygotes for classical homocystinuria, plasma protein-bound homocyt(e)ine was 3.5 and 4.8 nmole/ml, respectively. Untreated homozygotes showed approximately a 40-fold increase of plasma protein-bound homocyst(e)ine. Furthermore, using conventional methods, no free homocystine was detectable in the supernatant of plasma precipitate from two classical homocystinuric patients treated with pyridoxine, but plasma protein-bound homocyst(e)ine showed a 10-fold increase. Protein-bound homocyst(e)ine was also demonstrated in the liver, kidney, and brain tissues from a patient with methylenetetrahydrofolate reductase deficiency.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 503641     DOI: 10.1203/00006450-197910000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Protein-bound plasma homocyst(e)ine and identification of heterozygotes for cystathionine-synthase deficiency.

Authors:  R Sartorio; R Carrozzo; L Corbo; G Andria
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease.

Authors:  S S Kang; P W Wong; H Y Cook; M Norusis; J V Messer
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

3.  Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase.

Authors:  L Brattström; B Israelsson; L Tengborn; B Hultberg
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 4.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

5.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

6.  A study of cardiovascular risk in heterozygotes for homocystinuria.

Authors:  S H Mudd; R Havlik; H L Levy; V A McKusick; M Feinleib
Journal:  Am J Hum Genet       Date:  1981-11       Impact factor: 11.025

7.  Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations.

Authors:  S S Kang; P W Wong; H G Bock; A Horwitz; A Grix
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.